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Abstract 
The reduction of dehydroascorbate (DHA) to ascorbic acid is a vital cellular function. 
The omega class glutathione transferases catalyze several reductive reactions in cellular 
biochemistry, including DHA reduction. In humans, two isozymes (GSTO1-1 and 
GSTO2-2) with significant dehydroascorbate reductase activity are found, sharing 64% 
sequence identity. While the activity of GSTO2-2 is higher, it is significantly more 
unstable in vitro. We report the first crystal structures of human GSTO2-2, stabilized 
through site-directed mutagenesis, determined at 1.9 Å resolution in the presence and 
absence of glutathione. The structure of a human GSTO1-1 has been determined at 1.7 Å 
resolution in complex with the reaction product ascorbic acid, which unexpectedly binds 
in the G-site, where the glutamyl moiety of glutathione binds. The structure suggests a 
similar mode of ascorbate binding in GSTO2-2. This is the first time a non-glutathione-
based reaction product has been observed in the G-site of any GST. Ascorbic acid stacks 
against a conserved aromatic residue, F34 (equivalent to Y34 in GSTO2-2). Mutation of 
Y34 to alanine in GSTO2-2 eleminates dehydroascorbate reductase activity. From these 
structures and other biochemical data, we propose a mechanism of substrate binding and 
catalysis of dehydroascorbate reductase activity.  
 
Keywords: structure; ascorbic acid; reduction; enzyme mechanism; induced fit. 
Abbreviations: GST, glutathione transferase; GSH, glutathione; AA, ascorbic acid; DHA, 




Glutathione transferases (GSTs; E.C. 2.5.1.18) are a major class of phase II detoxification 
enzymes 
1
. Their main function is in the conjugation of endogenous or exogenous 
xenobiotic toxins with electrophilic centers to glutathione (-Glu-Cys-Gly, GSH), but 
several function as glutathione peroxidases or as reductases 
2
. The family of cytosolic 
GSTs comprises different classes including the omega class 
3
. Omega GST is a class with 
two different subunits (O1 and O2) 
4; 5
. The Omega class GSTs have been associated 
directly with several biological processes including the activation of IL-1 
6
 and the 
modulation of ryanodine receptors 
7
. Although the mechanism has not been elucidated, 
polymorphisms in the Omega class GSTs have been strongly associated with the age at 
onset of Alzheimer‟s and Parkinson‟s diseases 
8
 and a number of studies have reported 
associations with a range of disorders including familial amyotrophic lateral sclerosis 
9
 
and the development of acute childhood lymphoblastic leukemia 
10
. Specifically, genetic 
variation in GSTO2 has been associated with an increased risk of chronic obstructive 
pulmonary disease (COPD) 
11; 12
, urothelial carcinoma 
13




GSTO1-1 and GSTO2-2 show novel thiol transferase activity as well as dehydroascorbate 
(DHA) reductase and monomethylarsenate reductase activities 
4; 15; 16; 17
. We have 
previously shown that GSTO2-2 has higher DHA reductase (DHAR) activity than 
GSTO1-1 
17
 and is considered to be the most active DHAR in mammalian cells. This may 
be critical in the maintenance of ascorbic acid (AA) levels in the brain since they are 
dependent on the uptake and subsequent enzymatic reduction of DHA. AA plays a major 
role in scavenging free radical and specific reactive oxygen species 
18
 and the high 
 4 
consumption of oxygen in the brain suggests that a significant capacity to scavenge and 
detoxify these reactive species is required to prevent oxidative damage. Since the onset of 
neurological disorders such as Alzheimer's and Parkinson's diseases could be modulated 
by oxidative stress in the brain it is important to understand the structure and function of 
enzymes that play a significant role in regulating redox balance. Given the high level of 
conservation between human GSTO1-1 and GSTO2-2 sequences (64% identity at the 
amino acid level), it is likely that they operate by the same mechanism. We have 
previously determined the crystal structure of GSTO1-1 
4
 (PDB: 1EEM). Previous 
attempts to express recombinant human GSTO2-2 met with limited success due to poor 
expression and instability of the protein 
5
. Here, we describe a mutagenesis strategy that 
was used to improve the solubility and stability properties of GSTO2-2. Non-catalytic 
cysteine residues predicted to lie on the surface of GSTO2-2 (with potential to destabilize 
the protein through non-native disulfide bonds) were mutated to serine, and residues at 
the C-terminus were deleted in order to stabilize the enzyme. The modified protein 
retains 70% of the wild-type DHAR activity and it was sufficiently stable to enable 
structural and functional characterization. In order to understand the DHAR activity of 
omega-class GSTs, we determined the structure of a GSTO1-1 mutant in complex with 
the reaction product, AA. Together, the data lead us to propose a catalytic mechanism for 
DHAR activity in omega class GSTs and related enzymes. 
Results 
Expression, stability and catalytic analysis of GSTO2-2. 
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Recombinant GSTO2-2 proteins were prepared including wild type GSTO2 (wtGSTO2), 
GSTO2/MC6 (containing six cysteine to serine mutations), GSTO2/MC6D1 (same as 
MC6 with the C-terminal cysteine residue deleted), GSTO2/MC6D4 (same as MC6 with 
four residues as the C-terminus, FGLC, deleted), and GSTO2/D4 (four residues as the C-
terminus deleted). The exact modifications present in each mutant are detailed in Table 1. 
The proteins had varying degrees of solubility. GSTO2/MC6 remained in solution for one 
day at 4 °C and was comparable with wtGSTO2-2 in the same buffer but did not require 
0.5 M arginine as a stabilizing agent. Deletion of C-terminal residues of GSTO2/MC6 in 
GSTO2/MC6D1 and GSTO2/MC6D4 eliminated the precipitation at high protein 
concentration (above 5 mg/ml). GSTO2/MC6D1 and GSTO2/MC6D4 gradually 
precipitated and lost some DHAR activity after four days at 4° C. Protein stability was 
therefore increased with these modifications, with the most stable protein being 
GSTO2/MC6D4. 
 
The DHAR activity and the KM and kcat of wtGSTO2, GSTO2/MC6D1, GSTO2/MC6D4, 
and GSTO2/D4 were measured to determine if the modifications had a significant impact 
on function (Table 2). No activity loss was detected for GSTO2/MC6D1 compared with 
wtGSTO2, while GSTO2/MC6D4 maintained about 70% of wild type DHAR activity.  
Kinetic studies were limited by the high background rates that occur at high substrate 
concentrations (see methods) but relative comparisons can be made. MC6D1 and MC6D4 
had higher Kcat/GSH and Kcat/DHA than wtGSTO2-2 and GSTO2/D4 respectively 
indicating that the six Cys to Ser mutations increase the reaction turnover rate. The Cys to 
Ser mutations also increased the KM/GSH but not KM/DHA, (i.e. DHA binding is 
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unaffected but the affinity for GSH is reduced). Comparison of GSTO2/D4 and 
wtGSTO2, as well as GSTO2/MC6D4 and GSTO2/MC6D1, shows that a slightly lower 
KM/GSH and a significant lower (50 %) kcat were associated with the deletion of the 4 C-
terminal residues. Therefore, modification of the 6 cysteine residues may increase the 
activity and kcat by stabilizing the protein, while the integrity of the C-terminus may be 
important for the efficient turnover of the enzyme. 
 
Structure of GSTO2-2 
Three structures of GSTO2 have been determined from two crystal forms, in the absence 
(GSTO2/APO) and presence of GSH bound with partial (GSTO2/GSH) and full 
(GSTO2/GSH-2) occupancy (Table 3). The GSTO2-2 structures are homodimers (Figure 
1a, b) that share common features associated with cytosolic GSTs: an N-terminal 
thioredoxin-like domain and a C-terminal domain peculiar to the cytosolic GST 
superfamily (Figure 1c). Structure GSTO2/APO and structure GSTO2/GSH-2 protomers 
superimpose with a RMSD of 0.52 Å over 236 C atoms, demonstrating little 
perturbation due to different crystal contacts. GSTs typically feature a helix (2) 
contributing residues to the G-site. In the GSTO2-structure this is replaced with helix 
3101, which does not directly interact with GSH (Figure 1c). Like GSTO1, GSTO2 has an 
extended loop at the N-terminus and two helices at the C-terminus (8 and 3103) that are 
peculiar to the omega-class enzymes (Figure 1c). The binding location and orientation of 
GSH in the active sites of GSTO2 is typical of the superfamily (Figure 2b, c). 
Comparison of the apo- and GSH-bound forms of GSTO2-2 reveal that five water 
molecules in the G-site are directly displaced by GSH binding. The GSH-cystienyl 
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amino- and carbonyl-moieties make hydrogen bonds with L72 backbone (Figure 2b, c), 
and residue L72 is linked to P73 via a cis-peptide bond (Figure 2a, b, c). These features 
are observed in all GST structures determined to date. The GSH-glycinyl carboxylate 
moiety interacts via a salt-bridge with K59, located prior to helix 3101 in sequence. 
Several residues contact the GSH -glutamyl moiety. The R37 guanadinium-group forms 
a salt bridge with the GSH -glutamyl carboxylic acid group, which also accepts a H-
bond from S86 side chain-hydroxyl and main chain-amino groups. The aromatic portion 
of Y34 interacts with the aliphatic portion of the GSH -glutamyl moiety. An 
unanticipated cis-peptide link is observed between residues Y84 and E85 in structures 
GSTO2/APO and GSTO2/GSH (Figure 2a, b), but not in structure GSTO2/GSH-2 or in 
GSTO1 (Figure 2c, d), where the usual trans-conformation is observed. Residue E85 lies 
at the C-terminal end of strand 4 in the G-site. The introduction of a cis-peptide in 
structures GSTO2/APO and GSTO2/GSH prevent the E85 amino group from forming a 
hydrogen bond with the main chain carbonyl oxygen of P73, breaking the -strand 
conformation of this residue and causing strand 4 to terminate one residue early (Figure 
2a, b). In the GSTO2/APO and GSTO2/GSH structures, the E85 carboxylate interacts 
with the H71 imidazole ring (Figure 2a, b). In structure GSTO2/GSH-2, it is partially 
disordered, and two conformations are observed. Both conformers form a salt-bridge with 
the -glutamyl amino group of GSH (Figure 2c). The omega-class GSTs possess an active 
site cysteine (C32 in GSTO2) that forms a mixed disulfide with GSH, which is observed 
in structures GSTO2/GSH and GSTO2/GSH-2, and in GSTO1-1 (Figure 2b, c, d). C32 is 
located at the N-terminus of helix 1, with its thiol-group positioned over the helix axis. 
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The H-site in GSTO2-2 (Figure 2a, b, c) is co-localized with the equivalent site in 
GSTO1-1 (Figure 2d) and other GST classes. The N-terminal domain contributes 
residues F31 and P33 to the site. Residues R184 and Y188, at the C-terminal end of helix 
6, form one wall of the cavity. A well-ordered water molecule found in the cavity in all 
3 structures accepts hydrogen bonds from the R184-N and Y188-O groups, and 
donates a hydrogen bond to the F31 carbonyl (Figure 2a, b, c). The H-site is completed 
by residues from helix 8: F223, F226, L227 and Y230. In structure GSTO2/GSH-2, 
density lying between P33, F226 and Y230 was modeled as ethylene glycol. Comparison 
of structures GSTO2/APO and GSTO2/GSH show that 11 residues up to the C-terminus 
(which includes the C-terminal 4 residues of helix 8) become disordered upon GSH 
binding (Fig. 2b), however, no such disorder is observed in structure GSTO2/GSH-2. The 
reasons for this are not clear, but may involve different crystal contacts between 
GSTO2/APO and GSTO2/GSH (P21 symmetry) and GSTO2/GSH-2 (P6522 symmetry). 
In structure GSTO2/APO, the C-terminal end of helix 8 forms crystal contacts. In 
structure GSTO2/GSH-2, helix 3103 and parts of helix 8 are stabilized through crystal 
contacts.  
Crystal structure of GSTO1-1 with ascorbic acid 
The structure of GSTO1-1 C32S mutant with AA has been determined at 1.70 Å 
resolution (Table 3). In this structure, AA engages in -stacking with F34, 5 Å from the 
mutated C32S residue, occupying a portion of the „G-site‟ that typically binds the -
glutamyl moiety of GSH (Figure 2d). The opposite face of AA contacts the side chain of 




 is the altered conformer of E85, which is observed in two 
conformers, one the same as in the GSH-bound form of the enzyme and the second in a 
new conformation engaged in hydrogen-bonding interactions with the C6-hydroxyl of 
ascorbate and the side-chain hydroxyl of S86. The main chain amide of S86 also forms a 
hydrogen bond with its C5-hydroxyl. Other interactions within the active site include a 
hydrogen bond between its C3-hydroxyl group and the backbone carbonyl of V72. 
Electron density adjacent to AA was interpreted as an acetate ion, present in the buffer. 
One oxygen atom of the acetate ion was 2.65 Å from the serine hydroxyl group, and 
mediates an interaction between the S32-hydroxyl group and the C2-hydroxyl of 
ascorbate (Figure 2e). The other oxygen atom forms a hydrogen bond with a water 
molecule in the H-site. The methyl group of the acetate group stacks against the side of 
F34-phenyl group. 
Comparisons of GSTO2 with GSTO1 
The GSTO2 structure is broadly similar to that of GSTO1. Protomers of GSTO1 and 
GSTO2 structure GSTO2/GSH superimpose with a RMSD of 0.934 Å over 227 C 
atoms. Several features first observed in GSTO1 are conserved in GSTO2. These include 
the N-terminal extension that stacks against the side of the -sheet and the 8- and 3103-
helices that contributes to the distinctive shape of the active site (Figure 1c). The dimer 
interface of GSTO2-2 is slightly wider than that of GSTO1-1. Helix 4, the first helix in 
the C-terminal domain is kinked in both GSTO1 and 2. The G-sites of both isozymes are 
similar. The most significant differences between GSTO1 and O2 are found in the H-sites 
of the two enzymes. Relative to GSTO1, helix 8 in GSTO2 is shifted away from the G-
site by about 1.5 Å (Figure 2c, d). Residue Y230 in GSTO2 is rotated up and away from 
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the G-site compared with the equivalent Y229 in GSTO1. F223 in GSTO2 is substituted 
with W222 in GSTO1. The substitution of Y188 in GSTO2 with M187 in GSTO1 
(Figure 2d) creates space for the bulkier W222 side chain. These substitutions result in 
altered patterns of hydrogen bond donors in the two enzymes. GSTO2 has lost a 
hydrogen-bond donor due to the substitution of W222 for F223, and gained a hydrogen 
bond donor Y188-O. This donor, together with the hydrogen bond acceptor F31O and 
donor R184-N create the novel pocket that stabilizes a water molecule found in all 
GSTO2 structures. One point of similarity in the H-sites of the two isozymes is the W180 
residue and a structurally conserved water molecule that accepts a hydrogen bond from 
the side-chain amino group of this residue (Figure 2c, d). Both GSTO1-1 and GSTO2-2 
have positive electrostatic potential in their H-sites, although some differences were 
observed (Figure 3). This can be explained by substitution of R132 in GSTO1 with valine 
in GSTO2. Conversely, GSTO2 has gained a positive charge through substitution in the 
form of a lysine residue at position 128 (equivalent to G128 in GSTO1). The active site 
of GSTO2-2 is more occluded compared with GSTO1-1 due to the latter substitution and 
the rotation of residue Y230 (Y229 in GSTO1) into the opening of the H-site (Figure 2c). 
This rotation is caused by the substitution of C237 (in the C-terminal 310-helix of 
GSTO1) with a phenylalanine residue in GSTO2. 
 
Mutation of GSTO2 G-site residues  
To probe the significance of residues E85 and Y34 in GSTO2-2, two point mutants were 
created based on the GSTO2/MC6D1 construct: GSTO2/MC6D1-E85A and 
GSTO2/MC6D1-Y34A.  The E85A mutation of the GSTO2/MC6D1 protein diminished 
 11 
the DHAR activity by about 50 %. DHAR activity is eliminated in the Y34A mutant. 




The importance of human omega-class GSTs in reductive biochemistry, and their 
involvement in Alzheimer‟s and other diseases make them a worthy target for structural 
and functional characterization. The structure of hGSTO1 was reported previously 
4
, and 
here, we present the structure of hGSTO2-2 stabilized by mutagenesis. Although GSTO1 
and GSTO2 share over 60% sequence identity, they have different substrate specificities 
5; 19
. It appears likely that the differences in activity of the two isozymes are likely due to 
the differences in the H-sites described above. The location of Y230 and K128 in GSTO2 
creates a narrower entrance to the H-site, (Figure 2c, d). This reduction is consistent with 
the observed preference of GSTO2 for smaller substrates in comparison to GSTO1 
5; 19
. 
The conservation of an H-site water molecule in GSTO1 and O2, hydrogen bonded to 
W180-N1 may suggest a functionally conserved role (Figure 2c,d). 
 
Comparison of crystals structures of GSTO2-2 with unoccupied-, partially- and fully-
occupied G-sites allow changes due to GSH binding to be observed. No significant 
perturbations were observed upon GSH binding, with the exception of E85, which is in a 
cis-conformation in structures GSTO2/APO and GSTO2/GSH and in the trans-
conformation in GSTO2/GSH-2 (Figure 2a, b, c). In the latter case, the side-chain of E85 
forms a salt-bridge with the amino-group of the GSH--glutamyl amino-moiety. These 
 12 
observations hint at a novel induced-fit mechanism in GSTO2. Alternately, these 
structures may represent snapshots of the dynamic changes that occur in the protein in 
solution, the different forms of which are selected in the crystallization process. While the 
side chain of E85 contributes to the DHA reductase activity of the protein, the activity of 
the E85A mutant indicates that it is non-essential. The ability of the Y84-E85 peptide 
bond to adopt a cis-conformation could be responsible for the higher DHAR activity of 
GSTO2-2 compared with GSTO1-1. If the cis-conformation is favored in solution for 
GSTO2-2, E85 may be ideally pre-positioned to bind DHA, whereas in GSTO1-1, the 
side-chain must change conformation to interact with AA (Figure 2d, e). 
 
The observation of disorder in the C-terminal region structure GSTO2/GSH warrants 
comment. While crystal-packing effects cannot be ruled out, this phenomenon may 
reflect the inherent flexibility of this region of the protein. Instability in the C-terminal 
region of the wild-type protein, containing the four C-terminal residues FGLC, could lead 
to aggregation through non-specific hydrophobic interactions. 
 
Modified hGSTO2-2 (GSTO2/MC6D4) retains ~70% of the DHAR activity of wild type 
enzyme. Even though none of the modifications are found in the G- or H-site, they do 
have some effects on DHAR activity of GSTO2. The Cys to Ser mutations decrease the 
GSH affinity of the G-site but increase enzyme turnover rate, with a net higher reductase 
activity. Deletion of C-terminal FGLC residues reduces the enzyme turnover rate to less 
than half of the wild-type enzymes and increased the GSH affinity. While there is no 
indication that these residues could directly interact with GSH, the truncation could act to 
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destabilize the C-terminal region (as was observed in the GSTO2/GSH structure), leading 
to indirect effects on GSH binding. An induced-fit mechanism of GSH with the C-
terminus of the human GSTA1-1 has been observed 
20
. Notably, modifications to GSTO2 
made here have little effect on DHA-binding. 
 
Given their importance in reductive biochemistry, we sought to understand the DHAR 
activity of omega-class GSTs. The nature of DHA itself makes analysis of enzyme-
substrate interactions difficult: DHA reacts with water to form homicidal species (Figure 
4a) 
21
. Furthermore, DHA is unstable, degrading to several products via diketogulonic 
acid 
22
. A further complication arises from the formation of GSH-conjugates from these 
intermediates 
23
. We therefore pursued the structure of an omega-class GST with the 
more stable reaction product, AA. The binding of AA in the G-site of GSTO1-1 was 
unanticipated. Its occlusion of the G-site suggests product inhibition, an observation that 
contrasts with studies on the homologous Arabidopsis DHAR, where no evidence was 
found of product inhibition by Dixon and co-workers 
24
. However, the concentration of 
AA used here was much higher: 100 mM versus 5 mM by Dixon and co-workers. The 
binding of AA suggests that the enolic tautomeric form of DHA (protonated at O3) binds 
in the G-site as observed for AA (Figure 4b). An OH group at the 3‟-position is able to 
donate a hydrogen bond to the P73 carbonyl oxygen. A mechanism of Arabidopsis 
DHAR activity involving this tautomer of DHA has been outlined by Dixon and 
coworkers 
24
, and an analogous mechanism may operate in the omega-class GSTs in 
which the anionic form of C32 donates an electron to DHA to give the stable 
semidehydroascorbate radical, a well known intermediate in AA oxidation 
22
 (Figure 4c). 
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Abstraction of hydrogen from GSH results in AA formation. The resulting thiyl radicals 
of GS˙�and C32-S˙�would then terminate to form the glutathione-enzyme mixed 
disulfide. An alternative concerted mechanism is shown in Figure 4c. DHA is displaced 
by GSH binding with the concomitant reduction of DHA to AA by the enzyme and GSH, 
and a mixed enzyme/GSH disulfide is formed. 
 
In our model of DHA binding, the -stacking interaction of DHA with F34 plays a 
crucial role: the -stacking interaction would promote dehydration of the hemiacetal 
forms that would not interact favorably with the aromatic ring. In our model of DHA 
binding, GSH sulfhydryl must approach the exposed si face, giving the correct 
stereocenter at C4 upon transfer of hydrogen. Further evidence for the role of this 
aromatic group comes from the inactivity of the Y34A mutant. The mechanism is 
consistent with kinetic analysis of the spinach chloroplast DHAR (a GSTO homolog) 
which suggests binding of DHA to the reduced form of the enzyme prior to GSH 
25
. The 
activity of spinach chloroplast DHAR was inhibited by incubation with iodoacetic acid, 
shown to modify C23 (equivalent to C32 in GSTO1 and 2). This modification was 
suppressed by the addition of DHA, suggesting binding of this substrate close to this 
residue 
25
 which is consistent with our observation of AA binding close to C32 in 
GSTO1. The use of only the G-site for binding of both substrates is consistent with the 
lack of H-sites in proteins such as glutaredoxins, which contain G-site but not an H-site. 
The recently reported Phanerochaete chrysosporium GSTO1 structure has an H-site that 
appears largely occluded by the side-chains of tyrosine residues 
26
. This enzyme catalyzes 
DHA reduction and has a tryptophan residue (W88) in place of tyrosine (Y34) or 
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phenylalanine (F34) in GSTO2 and O1 respectively. The mechanism is consistent with 
conserved features in GSTO and all homologues with DHAR activity, including G-site 
cis-proline, G-site aromatic residue (F34 in GSTO1), and essential reactive cysteine 
(Figure 5). Our proposed mechanism does not involve a thiohemiketal intermediate, 
which was proposed for porcine glutaredoxin (thioltransferase) 
27
, since formation of a 





Materials and Methods 
Wild type protein expression and purification for GSTO2-2 
Human GSTO2 with a 6xHis tag was expressed in E. coli M15/rep4 cells using plasmid 
pQE30 (Qiagen) under control of the T5 promoter 
5
. Cultures were grown at 16 C. The 
protein was purified as described previously 
4
 with some modifications. Briefly, cells 
were harvested by centrifugation (4000 g for 10 min at 4 C) and resuspended in lysis 
buffer (phosphate buffered saline containing 15% glycerol, 0.3 M NaCl, 20 mM 
imidazole). Cells were lysed by passage through a French pressure cell and insoluble 
material was removed by centrifugation. All purification steps were undertaken at 4 C. 
The clarified lysate was mixed with Ni-NTA sepharose (50% slurry) equilibrated in the 
lysis buffer for 1 hour on a rotary mixer. Unbound protein was removed from the Ni-
NTA sepharose by copious washing on a sintered glass funnel. The washed sepharose 
beads were then placed in a chromatography column and the recombinant GSTO2-2 was 
eluted using lysis buffer containing 0.25 M imidazole, pH 7. Upon elution, arginine was 
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added to a final concentration of 0.5 M to prevent precipitation and encourage refolding. 
The purified protein was concentrated on a Falcon concentrator (BD Biosciences) to at 
least 10 mg/ml. The purity of the purified protein was assessed by SDS-PAGE and the 
protein was stored at -70 C. No activity loss was detected after 2 years of storage. In the 
absence of arginine and glycerol the protein precipitated quickly.  
Site-directed mutagenesis, purification and crystallization of GSTO2-2 
The consistent precipitation of the wild type GSTO2-2 protein during crystallization trials 
led us to investigate possible causes and remedies. Human GSTO2 has 11 cysteine 
residues compared with 5 in GSTO1. Beginning with the hypothesis that the abundance 
of cysteine residues contributed to the protein‟s instability, a model of GSTO2 was made 
using GSTO1 as a template in order to identify cysteine residues not near the active site 
and likely to be exposed to solvent. These were selected for mutation to serine. The 
following residues were mutated: C80, C121, C136, C140, C170, C214, to give 
“GSTO2/MC6”. A second construct “GSTO2/MC6D1” was created which contained the 
six aforementioned Cys to Ser mutations and deletion of the C-terminal residue (Cys243). 
Finally, a third construct “GSTO2/MC6D4” was made containing the six Cys to Ser 
mutations and the deletion of four residues (FGLC) at the C-terminus. To verify the 
effects of mutations and deletions on protein stability and activity, an extra construct 
“GSTO2/D4” was made only containing the deletion of four residues at C-terminus. To 
assess its functional importance, the strictly conserved G-site residue E85 (usually either 
E or Q in the cytosolic GST family) was mutated to A in the GSTO2/MC6D1 construct to 
create GSTO2/MC6D1-E85A. Similarly, to assess the importance of Y34 in the DHAR 
reaction mechanism it was mutated to A to create GSTO2/MC6D1-Y34A. All constructs 
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were cloned in pQE30 plasmid and expressed in E. coli M15/rep4 cells. The purified 
proteins retain a 6xH tag at the N-terminal.   The primers used for these mutations are 
listed in Table 4. 
 
The modified enzymes were expressed as soluble proteins at 37 C after induction by 0.1 
mM isopropyl-β-D-thiogalactopyranoside (IPTG). Proteins were purified as described for 
wild-type GSTO2-2 with some modifications to the buffer. Initial crystallization screens 
using wild type GSTO2-2 were unsuccessful. Examination of crystallization drops 
revealed that 2-Methyl-2,4-pentanediol (MPD) had a solublising effect on the protein. 
MPD was therefore added to the purification buffer. The modified GSTO2-2 proteins 
giving best crystals were obtained by Ni-affinity chromatography with the following 
buffer: 0.3 M NaCl, 25 mM imidazole, 3 % glucose, 5 % glycerol, 5 % MPD, 0.1 M 
MOPS pH 7.0. The elution buffer was identical except for the addition of imidazole to a 
concentration of 0.3 M. The purified protein was concentrated by dialysis against PEG 
7000-9000 using a 10 kDa cutoff dialysis membrane at 4 C overnight. The purity of 
proteins was assessed by SDS-PAGE and gel filtration on a Superose-12 column 
(Pharmacia).  Recombinant wild-type GSTO2-2 is very unstable and precipitates during 
the purification procedure. The improved relative stability of the mutant isoforms was 
evaluated by their capacity to resist precipitation and inactivation during purification and 
during storage at 4 C.  
 
Crystallization screens were performed on the GSTO2/MC6D1 and GSTO2/MC6D4 
proteins that had been concentrated to around 10 mg/ml. The sitting-drop vapor diffusion 
 18 
method in a 96 well tray format as used with Crystal Screens 1 and 2 (Hampton Research, 
CA). Equal volumes (1 l) of protein and reservoir solution were mixed in the drop 
receptacles prior to sealing the tray for equilibration at 4 C. For X-ray data collection, 
crystals were grown by the hanging-drop vapor diffusion method using 24-well trays 
(Greiner Bio-One, CA) at 18 C. Solutions of protein and precipitant (1.5 l each) were 
mixed on siliconized cover slips (Hampton Research) prior to suspension over 0.5 ml of 
reservoir solution. Microseeds were made by the ultrasonicated bead method 
28
 and used 
to assist the discovery of crystallization conditions: screening was performed as described 
above except with the addition of 0.1 l of seed solution. 
 
While variants GSTO2/MC6D1 and GSTO2/MC6D4 were subjected to crystallization 
trials, only GSTO2/MC6D4 gave diffraction-quality crystals. The best crystals were 
found with condition 46 of Crystal Screen 2 (0.1 M sodium chloride, 0.1 M Bicine pH 
9.0, 20 % (w/v) PEGMME 2000). Optimal crystals grown using the hanging-drop vapor 
diffusion technique were rods of dimension 30  30  200 m. One data set 
(GSTO2/APO) was collected from a single crystal of GSTO2/MC6D4, and a second 
collected (GSTO2/GSH) from a crystal grown under the same conditions but with 20 mM 
GSH added (see below). A second crystal habit (hexagonal bipyramids) was found with 
condition 39 of Crystal Screen 1 (0.1M Hepes pH7.5, 2% v/v Polyethylene glycol 400, 
2M ammonium sulfate). These crystals appeared upon microseeding with monoclinic 
crystals sourced from condition 46 of Crystal Screen 2. Optimal numbers and sizes of 
crystals were obtained using a 1000-fold dilution of seed stock and a protein 
concentration of about 5 mg/ml with 20 mM GSH in condition 39 of Crystal Screen 1. 
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The best crystals had dimension 30  30  30 m and a dataset (GSTO2/GSH-2) was 
collected from one of these crystals as described below. 
Site-directed mutagenesis, Purification and crystallization of GSTO1-1 
Repeated soaking experiments of wild-type human GSTO1, and GSTO2/MC6D4 crystals 
failed to yield a crystal structure with bound AA. Hypothesizing that a catalytically 
incompetent mutant might allow visualization the reaction product, we created a GSTO1-
C32S mutant, which is unable to form a mixed-disulfide with GSH. The construct was 
cloned into the pHUE vector and expressed as a 6xHis-tagged fusion protein with 
ubiquitin in E. coli BL21 cells as described previously 
29
. The primers used to make the 
C32S mutation are shown in Table 4. Protein expression was induced by 50 M IPTG at 
37 C and purified using Ni-affinity chromatography. Finally the 6x-His-ubiquitin 
portion was cleaved and removed as described previously 
29
. Protein solutions were 
dialysed overnight against 60 mM NaCl, 20 mM Tris, 5 mM DTT, pH 8 at 4 C before 
concentrating to 25 mg/ml using a 10 kDa cutoff Amicon Ultra centrifugal device 
(Millipore, Cork, Ireland). Purity was assessed by SDS-PAGE. 
 
The hGSTO1-1 C32S mutant was crystallized using the hanging drop vapor diffusion 
method. Optimal crystal growth was modified from conditions previously published 
4
. 
The reservoir consisted 2.2 M (NH4)2SO4 and 100 mM Sodium Acetate, pH 4.75. 1 l of 
protein was mixed with 1 l L-ascorbate (100 mM), 1 l of a saturated solution of -
tocopherol succinate (an uncompetitive inhibitor 
30
) and 1 l of reservoir solution. 
X-ray data Collection and crystal structure determination 
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All X-ray data were collected at the Australian synchrotron, beam line MX1. Crystal 





 was used for structure refinement including TLS refinement 
33
. Occupancy 
refinement was performed in PHENIX 
34
. Model building and electrostatic surface 
calculations were performed using COOT 
35
. 
Diffraction data of Crystals GSTO2/APO and GSTO2/GSH were processed by 
MOSFLM of CCP4 suite 
36
. Crystals GSTO2/GSH-2 and GSTO1/AA was processed 
using the HKL package 
37
. The structure GSTO2/APO was solved using the hGSTO1 
crystal structure (PDB id 1EEM). The crystals belong to space group of P21 with a 
physiological dimer in the asymmetric unit. After several rounds of restrained refinement 
in REFMAC and manual model building in COOT, the R and Rfree reduced to 0.19 and 
0.24 respectively. An ethylene glycol monomer, one glycerol molecule and two chloride 
ions were added to the model together with water molecules in the final stages of model 
building. No GSH was observed to bind in the G-site. This structure was used as the 
starting model for structures GSTO2/GSH and GSTO2/GSH-2. Structure GSTO2/GSH 
was isomorphous with structure GSTO2/APO. Additional density (>1σ) in the 2mFo-DFc 
was observed in the active sites in both protomers, corresponding to GSH binding. Good 
density was observed for the -glutamyl and cysteinyl residues, but electron density was 
poor for the glycine moiety. Occupancy refinement in PHENIX suite gave partial 
occupancy of 0.62 and 0.71 for GSH in each G-site. Two PEG molecules and chloride 
ions were added to structure GSTO2/GSH-2 in addition to water molecules. Initial 
processing of dataset GSTO2/GSH-2 revealed a hexagonal Bravis lattice. Merging in 
SCALEPACK and examination of systematically absent reflections indicated space group 
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P6122 or its enantiomorph P6522. The correct space group (P6522) was identified by 
PHASER. The asymmetric unit contained a GSTO2/MC6D4 protomer, which lies upon a 
crystallographic 2-fold axis to give a physiological dimer. Inspection of 2mFo-DFc 
electron density maps revealed clear (>1.5σ) electron density for GSH. The GSTO1/AA 
structure is isomorphous with the previously reported structure of GSTO1 with GSH 
4
 
(PDB: 1EEM). This structure, with ligands and water molecules removed, was used as 
the starting model for refinement. Sulfate and glycerol molecules were built into the 
model and AA was included in the final stages of refinement. All refinement statistics 
were shown in Table 3. 
Enzyme activity assay 
Dehydroascorbate reductase (DHAR) activity was measured spectrophotometrically by 
recording the increase in absorbance at 265 nm as described previously 
17
.  The reaction 
mix contained of 200mM Na phosphate and 1mM EDTA, pH6.85, 2.25mM GSH, and 
1mM DHA in a total volume of 1 ml. The reaction was started by the addition of DHA 
and  recorded  for 2 minutes at 30C with a 1cm light path.  The reaction rate was 
calculated using an extinction coefficient of 14.7mM/cm.  DHA was prepared from 




For the determination of the Michaelis-Menten constant (Km) for GSH, the DHA 
concentration was kept to 1mM, while GSH concentration was varied from 0.25 mM to 4 
mM. For the KM of DHA, GSH concentration was kept at 2.25 mM, while DHA was 
varied from 0.1 to 2 mM.  Because very high back round rates occur at high GSH and 
high DHA concentrations the reaction rates could not be determined under saturating 
conditions. Consequently the concentration of GSH used for the determination of the Km 
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(DHA) was below the Km (GSH) and not saturating. As a result the Kcat was lower when 
DHA was varied than when GSH was varied and the values are presented separately in 
Table2.  Despite the non-saturating conditions, relative comparisons between the mutated 
isoforms can still be made 
Accession numbers 
All structures and X-ray structure factors have been deposited at the PDB. Accession 
numbers: 3Q18, 3Q19, 3QAG and 3VLN. 
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Figure 1. Cartoon representation of the GSTO2/MC6D4. Shown are the dimer (a), 
with an orthogonal view (b), and protomer with secondary structure labels (c). GSH is 
shown in stick form. All figures were drawn using VMD 
39
. In (c) the N-terminal and C-
terminal regions peculiar to the omega-class GSTs are highlighted in green red 
respectively.  
 
Figure 2. Stereodiagrams of GSTO active sites. The active sites of (a) GSTO2/APO, 
(b) GSTO2/GSH, (c) GSTO2/GSH-2, (d) GSTO1 (pdb 1EEM) and (e) GSTO1 with AA. 
(f) close-up of the AA binding site. The protein backbone is shown in cartoon form (β-
strands yellow; -helices magenta; 310-helices blue), and active-site residues in stick 
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form. The carbon atoms are coloured cyan (G-site residues), black (H-site residues) or 
orange (catalytic cysteine and ligands). Thin black lines indicate hydrogen bonds. The 
cis-peptide link between Y84 and E85 is indicated with a star (a, b). 
 
Figure 3. Electrostatic potential surfaces of GSTO active sites. (a) structure of GSTO1 
with GSH and (b) GSTO2 with GSH. The protein surfaces are colored red (negative 
potential) through white (neutral) and blue (positive potential). 
 
Figure 4. Proposed mechanisms of DHAR activity. (a) DHA and the dominant 
hemiketal form in aqueous solution. (b) Proposed mode of binding of DHA in omega-
class GSTs. (c) Proposed DHAR reaction mechanism by single electron transfer. (d) An 
alternative concerted mechanism for DHAR activity. 
 
Figure 5. Structure-based sequence alignment of human GSTO2 (hGSTO2), GSTO1 
(hGSTO1, PDB ID: 1EEM), fungal GSTO homolog from Phanerochaete chrysosporium 
(fGSTX, PDB ID: 3PPU) and porcine glutaredoxin (pGRX, PDB ID: 1KTE). The 
locations of -strands are indicated by underlined residues, helices are indicated by 
strike-through. Those residues in GSTO1 interacting with AA, and their equivalents in 
other structures are highlighted in yellow. 
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Tables 
Table 1. Abbreviations used for the wild-type and mutant enzymes and the mutations 
they contain. 
Enzyme Mutations 
wtGSTO2-2 Wild-type, 243 normal residues. 
GSTO2/MC6 C80S, C121S, C136S, C140S, C170S, C214S.  
GSTO2/MC6D1 C80S, C121S, C136S, C140S, C170S, C214S, C243 at C-
terminus. 
GSTO2/MC6D4 C80S, C121S, C136S, C140S, C170S, C214S, FGLC at C-
terminus.  




Table 2. Activity and kinetic analysis of various modified hGSTO2 proteins 
 wtGSTO2 MC6D1 MC6D4 D4 MC6D1-E85A 
Activity
a
 14.65±0.93 16.11±0.68 9.28±0.49 4.88±0.35 8.01±0.46 
      
Km/GSH
b
 4.82±0.83 7.80±0.46 5.97±1.32 4.18±0.93 ND 
kcat/GSH
c
 1.05±0.12 1.76±0.08 0.83±0.13 0.35±0.05 ND 
      
Km/DHA
b
 0.51±0.05 0.52±0.06 0.43±0.05 0.53±0.06 ND 
kcat/DHA
c
 0.66±0.03 0.81±0.04 0.48±0.02 0.28±0.01 ND 
a






 ;ND, not determined. 
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Table 3. X-ray data collection and refinement statistics. 
Structure GSTO2/APO GSTO2/GSH GSTO2/GSH
-2 
GSTO1/AA 
PDB ID 3Q18 3Q19 3QAG 3VLN 
Space group P21 P21 P6522 P3121 
Cell dimensions     
a 46.7 46.4 53.1 56.9 
b 85.7 85.0 53.1 56.9 
c 60.4 60.4 352.4 140.51 
  = 95.3  = 94.6   










Completeness (%) 93.4 (87.9) 92.9 (85.2) 98.63 (99.54) 99.2 (98.7) 
Number of reflections 48429 (6623) 34258 (4571) 19842 (1428) 29768 (2912) 
Rmerge
a
 (%) 4.2 (22.3) 5.4 (15.5) 8.4 (34.6) 6.1 (69.6) 
I/σ 14.3 (3.5) 10.5 (3.9) 21.9 (4.6) 40.9 (4.14) 
Refinement 
R-factor (%) 15.7 16.4 22.4 18.0 
Rfree (5% of data) 18.6 19.4 26.5 21.7 
RMSD from ideal geometry 
Bonds (Å) 0.007 0.009 0.009 0.020 
Angles (°) 1.03 1.13 1.18 1.87 
Chiral volumes (Å
3
) 0.059 0.064 0.083 0.112 
Average temperature factor (B): 
Protein 11.47 22.8 22.1 17.7 
Ligand  36.2 28.4 37.6 




Most favoured region 98.7 97.6 97.5 98.7 
Allowed region 1.1 2.2 2.1 0.9 
outlier region 0.2 0.2 0.4 0.4 
Residues covered by 
electron density: 
    
Protomer A 4-239 5-228 2-239 3-241 
Protomer B 7-239 7-239   
a
, Rmerge=Σ І-‹I› Σ‹I›; 
b




, highest resolution bin. 
 4 
Table 4. Primers used in the genetic manipulation of hGSTO2-pQE30 and hGSTO1-
pHUE. 





Reverse  5’-CTGAAGCTTTCAGCACAGCCCAAAGTC-3’ 
C80S primer pair 
Forward 5’-GACCAGCCAATCTCAACTGAT-3’ 
Reverse  5’-CATAGATCAGTTGAGATTGGCT-3’ 
C121S primer pair 
Forward 5’-GGAGCTATTTTCTAAGGTCCCA-3’ 
Reverse  5’-GTGGGACCTTAGAAAATAGCA-3’ 
C136S primer pair 
Forward 5’-GGTAGCGTTGAGATCTGGGAGAGA-3’ 
Reverse  5’-CATTCTCTCCCAGATCTCAACGCT-3’ 
C140S primer pair 
Forward 5’-GTGGGAGAGAAAGCACTAATCT-3’ 
Reverse  5’-CCTTCAGATTAGTGCTTTCTCT-3’ 
C170S primer pair 
Forward 5’-CTTTGGTGGAACCTCTATATCCAT-3’ 
Reverse  5’-CAATCATGGATATAGAGGTTCCA-3’ 
C214S primer pair 
Forward 5’-CCCCACAGTCTCAGCTCTTCT-3’ 




FGL deleting primer Reverse  5’-CTAATTAAGCTTTCAGTCAAAGGCAT-3’ 
E85A primer pair 
Forward 5’-GCCAATCTCAACTGATCTATGCATCTGTT-3’ 
Reverse  5’-CACAAGCAATAACTGATGCATAGAT-3’ 






Reverse  5’-TCCAAGAGGGCAAACGAC-3’ 
a




































































































































































































































                                                    β1 
hGSTO2 -------------------msgdatrtlgkgsqppgpvpegLIRIYSMR 
hGSTO1 -------------------msgesarslgkgsappgpvpegSIRIYSMR 
fGSTX  elqsdiskmkteddgsfkrkaasfrnwiqpngdftftpekgRYHLYVSY 
pGRX   ----------------------------maqafvnskiqpgKVVVFIKP 
 
              α1               β2 
hGSTO2 FCPYSHRTRLVLKAKdi----RHEVvninlrnkp--------------- 
hGSTO1 FCPFAERTRLVLKAKgi----RHEVininlknkp--------------- 
fGSTX  ACPWATRTLIVRKLKgle-dfIGVTvvsprmgsngwpfanvdpfpaads 
pGRX   TCPFCRKTQELLSQLpfkeglLEFVditatsdtneiqdylq-------- 
 
                      3101          β3      β4     α3 
hGSTO2 --------------ewyytkhpfgHIPVLEtsq--cqLIYeSVIACEyl 
hGSTO1 --------------ewffkknpfgLVPVLEnsq--gqLIYeSAITCEyl 
fGSTX  dplnnaqhvkdlylkvkpdydgrfTVPVLWdkhtgtiVNNeSSEIIRmf 
pGRX   ------------------qltgarTVPRVFigk---eCIGgCTDLESmh 
 
                                  α4a             α4b 
hGSTO2 ddaypg------rklfpydpYERARQKMLLELFck-vphltkeclvalr 
hGSTO1 deaypg------kkllpddpYEKACQKMILELFsk-vpslvgsfirsqn 
fGSTX  ntafnhllpedkakldlypeSLRAKIDEVNDWVydtvnngvyksgfast 
pGRX   krgelltrlqqigalk--------------------------------- 
 
                      α5                         α6 
hGSTO2 cgrectnlkaaLRQEFSNLEEIleyqnttffggtcISMIDYLLWPWFER 
hGSTO1 -kedyaglkeeFRKEFTKLEEVltnkkttffggnsISMIDYLIWPWFER 
fGSTX  -qkayeaavipLFESLDRLEKMlegq-dyli-ggqLTEADIRLFVTIVR 
pGRX   ------------------------------------------------- 
 
              3102              α7a          α7b      α8  
hGSTO2 LDVYgildcvs-------htpALRLWISAMKw-dpTVCALlmdkSIFQG 
hGSTO1 LEAMklnecvd-------htpKLKLWMAAMKe-dpTVSALltseKDWQG 
fGSTX  FDPVyvthfkcnlrtirdgypNLHRWMRKLYwgnpAFKDTcn-fEHIKT 
pGRX   ------------------------------------------------- 
 
                 3103 
hGSTO2 FLNLYfqnnpnafdfglc 
hGSTO1 FLELYlqnspeacdygl 
fGSTX  HYFWShtfinphrivpigpipdilpld 
pGRX   --------------------------- 
 
Figure 5
